Key Highlights
•
A new study shows that combining an HDAC6 inhibitor with standard SMN2 splicing modifier therapy significantly improves muscle strength, mass, and survival in a mouse model of spinal muscular atrophy (SMA).
Source →
•
This dual-therapy approach targets the persistent muscle weakness and atrophy that remain a problem for children with SMA even after gene therapy, making HDAC6 inhibitors a promising candidate to improve long-term outcomes.
Source →
•
Living closer to a lead-releasing facility is linked to lower memory scores, with every 5 kilometers closer associated with a 0.05 standard deviation decrease in episodic memory two years later.
Source →
•
This research from diverse U.S. cohorts provides strong evidence that adult lead exposure from industrial sources can silently harm brain health, highlighting a modifiable environmental risk factor for cognitive decline.
Source →
•
Researchers found that seronegative autoimmune hepatitis (SnAIH) is a rare condition, affecting only about 1% of patients, and is often misdiagnosed due to incomplete autoantibody testing.
Source →
•
The findings emphasize the critical need for standardized and comprehensive autoantibody screening according to medical guidelines to avoid missing this treatable liver disease and to ensure patients receive proper care.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
